cerapedics

Biologics

Josh SandbergJanuary 4, 2024
279

Cerapedics Files Final Module of the PMA Application for FDA Approval of a new P-15 Peptide Enhanced Bone Graft for Lumbar Spine Fusion

If approved, the breakthrough product will bring Cerapedics’ P-15 Peptide to lumbar spine fusion with a TLIF indication, making it…
Read More »
Biologics

Josh SandbergOctober 17, 2023
136

Cerapedics Reinforces Commitment to Level 1 Evidence with Long-Term Results from Six-Year Pivotal IDE Cervical Study Demonstrating 98.6% Spine Fusion Rates in Patients Treated With i-FACTOR®

WESTMINSTER, Colo., Oct. 17, 2023 /PRNewswire/ — Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone…
Read More »
Biologics

Josh SandbergJuly 19, 2023
232

Cerapedics™ Announces Expansion of Headquarters to Support Growth of its Bone Graft Products

WESTMINSTER, Colo., July 19, 2023 /PRNewswire/ — Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair,…
Read More »
Biologics

Josh SandbergOctober 10, 2022
314

Cerapedics Appoints Valeska Schroeder Chairman and Chief Executive Officer

WESTMINSTER, Colo., Oct. 10, 2022 /PRNewswire/ — Cerapedics Inc., a commercial-stage ortho-biologics company dedicated to enhancing the science of bone repair, announced…
Read More »
Biologics

Chris J. StewartFebruary 24, 2022
1,098

Cerapedics Completes Enrollment of Pivotal U.S. FDA IDE Study for its P-15L Bone Graft

The ASPIRE study is intended to evaluate the use of P-15L Bone Graft in transforaminal lumbar interbody fusion surgery in…
Read More »
Biologics

Josh SandbergAugust 17, 2021
5,636

Cerapedics Announces Publication of Results of Study Evaluating the Cost-Effectiveness of i-FACTOR vs. Local Autologous Bone in ACDF Surgery

Data published in ClinicoEconomics and Outcomes Research show that the novel i-FACTOR is not only cost-effective compared to autograft in…
Read More »
Biologics

Josh SandbergApril 29, 2021
435

Cerapedics Announces FDA Breakthrough Device Designation Granted for P-15L Bone Graft for the Treatment of Degenerative Disc Disease

– P-15L Bone Graft is currently being studied in the Company’s ASPIRE IDE clinical trial – WESTMINSTER, Colo., April 29, 2021 /PRNewswire/…
Read More »
Biologics

Josh SandbergNovember 5, 2020
617

Cerapedics Announces Commercial Launch of i-FACTOR®+ Matrix in Canada

Canada will be the first commercial market to launch i-FACTOR®+ Matrix WESTMINSTER, Colo., Nov. 5, 2020 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today…
Read More »
Biologics

Josh SandbergSeptember 15, 2020
588

Cerapedics Announces Canadian Approval of its next-generation bone graft

Canada will be the first commercial market to launch i-FACTOR®+ Matrix WESTMINSTER, Colo., September 15, 2020 — Cerapedics, a private…
Read More »
Biologics

Josh SandbergJuly 22, 2020
668

Cerapedics Announces FDA approval of an IDE supplement

WESTMINSTER, Colo., July 22, 2020 — Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA)…
Read More »
Biologics

Josh SandbergMay 19, 2020
1,137

Cerapedics Announces Results from Clinical Trial of i-FACTOR® Peptide Enhanced Bone Graft in Lumbar Fusion Surgery

WESTMINSTER, Colo., May 19, 2020 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide…
Read More »
Biologics

Josh SandbergNovember 18, 2019
697

Cerapedics Announces FDA Approval of PMA Supplement Based on Two-Year Clinical Data

WESTMINSTER, Colo., Nov. 18, 2019 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA) has…
Read More »
Biologics

Josh SandbergJuly 8, 2019
1,403

Cerapedics Announces Expansion of Colorado Headquarters

WESTMINSTER, Colo., July 8, 2019 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced the expansion of the company’s headquarters located in the Denver metropolitan…
Read More »
Biologics

Josh SandbergJune 24, 2019
1,047

Cerapedics Appoints Patrick O’Connor as Vice President of Clinical and Market Development

WESTMINSTER, Colo., June 24, 2019 /PRNewswire/ –Cerapedics, a privately-held orthobiologics company, today announced the appointment of Patrick O’Connor as Vice President of Clinical and…
Read More »
Biologics

Josh SandbergMarch 6, 2019
1,048

Cerapedics Announces ISASS Issued a new Bone Grafting Policy Statement that Features i-FACTOR™ Peptide Enhanced Bone Graft

WESTMINSTER, Colo., March 6, 2019 /PRNewswire/ –Cerapedics, a privately-held orthobiologics company, today announced that the International Society for the Advancement of Spine…
Read More »